Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia

Translational Stroke Research

Volumn 2, Issue 3, 2011, Pages 404-410

  Akiyoshi, Kozaburo ^a,c   Dziennis, Suzan ^a,b   Palmateer, Julie ^a   Ren, Xuefang ^a,b   Vandenbark, Arthur A ^a,b   Offner, Halina ^a,b   Herson, Paco S ^a   Hurn, Patricia D ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Cerebral infarction; Cerebral ischemia; Immunotherapy; Inflammation; Middle cerebral artery occlusion; Mouse; Stroke; T lymphocyte

Indexed keywords

IMMUNOMODULATING AGENT; RECOMBINANT T CELL RECEPTOR LIGAND; RECOMBINANT T CELL RECEPTOR LIGAND 1000; RECOMBINANT T CELL RECEPTOR LIGAND 551; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 80052268543     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0085-1     Document Type: Article

References (23)

1. Ahmad M, Graham SH. Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res. 2010; 1: 74-84.
2. Burrows GG, Chang JW, Bachinger HP, Bourdette DN, Offner H, Vandenbark AA. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999; 12: 771-8.
3. Emsley HC, Smith CJ, Georgiou RF, Vail A, Tyrrell PJ, Barberan EM, et al. Correlation of systemic inflammatory response with infarct volume in acute ischemic stroke patients. Stroke. 2005; 36: 228-9.
4. Finn TP, Jones RE, Rich C, Dahan R, Link J, David CS, et al. HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. J Neurosci Res. 2004; 78: 100-14.
5. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009; 40: 1849-57.
6. Gonzalez-Gay MA, Zanelli E, Khare SD, Krco CJ, Zhou P, Inoko H, et al. Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice. Hum Immunol. 1996; 50: 54-60.
7. Herson PS, Palmateer J, Hurn PD, DeVries AC. Evaluating behavioral outcomes from ischemic brain injury. In: Raber J, editor. Translational animal models of behavioral analysis. New York: Humana; 2010.
8. Huan J, Kaler LJ, Mooney JL, Subramanian S, Hopke C, Vandenbark AA, et al. MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J Immunol. 2008; 180: 1249-57.
9. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010; 115: 3835-42.
10. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol. 2004; 187: 94-104.
11. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009; 15: 192-9.
12. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De SG, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121: e46-e215.
13. Maeda K, Hata R, Hossmann KA. Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice. Neuroreport. 1998; 9: 1317-9.
14. Noskin O, Krakauer JW, Lazar RM, Festa JR, Handy C, O'Brien KA, et al. Ipsilateral motor dysfunction from unilateral stroke: implications for the functional neuroanatomy of hemiparesis. J Neurol Neurosurg Psychiatry. 2008; 79: 401-6.
15. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006; 26: 654-65.
16. Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA. RTL therapy for multiple sclerosis: a phase I clinical study. J Neuroimmunol. 2010; 231(1-2): 7-14.
17. Schaefer SY, Haaland KY, Sainburg RL. Ipsilesional motor deficits following stroke reflect hemispheric specializations for movement control. Brain. 2007; 130: 2146-58.
18. Sinha S, Subramanian S, Proctor TM, Kaler LJ, Grafe M, Dahan R, et al. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci. 2007; 27: 12531-9.
19. Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, Grafe M, et al. Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol. 2010; 5: 231-9.
20. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004; 4: 2.
21. Subramanian S, Zhang B, Kosaka Y, Burrows GG, Grafe MR, Vandenbark AA, et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke. 2009; 40: 2539-45.
22. Uchida M, Palmateer JM, Herson PS, DeVries AC, Cheng J, Hurn PD. Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice. J Cereb Blood Flow Metab. 2009; 29: 1454-62.
23. Zhu W, Wang L, Zhang L, Palmateer JM, Libal NL, Hurn PD, et al. Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-dependent in male mice. Neuroscience. 2010; 169: 758-69.